Surgery: light – thermal – and electrical application – Light – thermal – and electrical application – Electrical therapeutic systems
Reexamination Certificate
2001-01-04
2003-12-23
Vo, Hieu T (Department: 3762)
Surgery: light, thermal, and electrical application
Light, thermal, and electrical application
Electrical therapeutic systems
C607S008000, C607S014000, C607S016000
Reexamination Certificate
active
06668193
ABSTRACT:
FIELD OF THE INVENTION
This invention pertains to apparatus and methods for treating cardiac arrhythmias. In particular, the invention relates to an apparatus and method for electrically terminating tachyarrhythmias.
BACKGROUND
Tachyarrhythmias are abnormal heart rhythms characterized by a rapid heart rate. Examples of tachyarrhythmias include supraventricular tachycardias such as sinus tachycardia, atrial tachycardia, and atrial fibrillation (AF), and ventricular tachyarrhythmias such as ventricular tachycardia (VT) and ventricular fibrillation (VF). Both ventricular tachycardia and ventricular fibrillation are hemodynamically compromising, and both can be life-threatening. Ventricular fibrillation, however, causes circulatory arrest within seconds and is the most common cause of sudden cardiac death. Atrial fibrillation is not immediately life threatening, but since atrial contraction is lost, the ventricles are not filled to capacity before systole which reduces cardiac output. This may cause lightheadedness or fainting in some individuals, as well as fatigue and shortness of breath, hindering the individual from carrying out normal daily activities. If atrial fibrillation remains untreated for long periods of time, it can also cause blood to clot in the left atrium, possibly forming emboli and placing patients at risk for stroke.
Cardioversion (an electrical shock delivered to the heart synchronously with an intrinsic depolarization) and defibrillation (an electrical shock delivered without such synchronization) can be used to terminate most tachyarrhythmias, including AF, VT, and VF. As used herein, the term defibrillation should be taken to mean an electrical shock delivered either synchronously or not in order to terminate a fibrillation. In electrical defibrillation, a current depolarizes a critical mass of myocardial cells so that the remaining myocardial cells are not sufficient to sustain the fibrillation. The electric shock may thus terminate the tachyarrhythmia by depolarizing excitable myocardium, which thereby prolongs refractoriness, interrupts reentrant circuits, and discharges excitatory foci.
Implantable cardioverter/defibrillators (ICDs) provide electrotherapy by delivering a shock pulse to the heart when fibrillation is detected by the device. The ICD is a computerized device containing a pulse generator that is usually implanted into the chest or abdominal wall. Electrodes connected by leads to the ICD are placed on the heart, or passed transvenously into the heart, to sense cardiac activity and to conduct the impulses from the pulse generator. Typically, the leads have electrically conductive coils along their length that act as electrodes. ICDs can be designed to treat either atrial or ventricular tachyarrhythmias, or both, by delivering a shock pulse that impresses an electric field between the electrodes to which the pulse generator terminals are connected. The electric field vector applied to the heart is determined by the magnitude of the voltage pulse and the physical arrangement of the shocking electrodes, which may serve to concentrate the field in a particular region of the heart. Thus, the particular electrode arrangement used will dictate how much depolarizing current is necessary in order to terminate a given tachyarrhythmia.
Ventricular and atrial fibrillation are phenomena that exhibit a threshold with respect to the shock magnitude and duration needed to terminate the fibrillation by changing the transmembrane potential in a critical mass of myocardial cells. The ventricular defibrillation threshold (VDFT), for example, is the smallest amount of energy that can be delivered to the heart to reliably convert ventricular fibrillation to normal sinus rhythm. Similarly, the atrial defibrillation threshold (ADFT) is the threshold amount of energy that will terminate an atrial fibrillation. The larger the magnitude of the shocks delivered by an ICD, the more the battery is drained, thus decreasing the longevity of the device. It is desirable, therefore, for the defibrillation threshold to be as small as possible in order to minimize the amount of shocking current that the ICD must deliver in order to terminate a given tachyarrhythmia.
Electrode arrangements have been devised in an attempt to minimize the defibrillation threshold for particular types of tachyarrhythmias. For example, the traditional configuration for ventricular defibrillation is to place a cathodic electrode in the right ventricle, with the anode formed jointly by an electrode placed in the superior vena cava and the conductive housing of the ICD acting as an additional electrode. For treating atrial fibrillation, a conventional electrode configuration is to use electrodes disposed within the coronary sinus and in the right atrium. In addition, the waveform of the shocking pulse also affects the defibrillation threshold. ICDs use a capacitor discharge system for delivering shock pulses in which a charged capacitor is connected to the shock electrodes to deliver current to the myocardium. Because of space constraints, the size of a typical capacitor is limited and thus exhibits a significant exponential decay when connected to the load (i.e., a small RC time constant). Rather than allowing the decay to continue when the capacitor is connected across the load, solid-state switches may be used to sharply truncate the waveform which may result in a lower energy requirement for defibrillation. ICDs also commonly employ a biphasic shock pulse waveform in which the polarity of the waveform reverses during the shock pulse, a technique that has been found to further lower the defibrillation threshold. (See U.S. Pat. No. 4,998,531, hereby incorporated by reference.)
In order to further improve safety and avoid unnecessary discomfort for ICD patients, there is a continuing need for methods and apparatus that improve the efficiency of electrical defibrillation and thereby reduce the defibrillation threshold. Such reductions in defibrillation thresholds may also expand the population of patients for whom ICDs are an appropriate therapeutic option. It is toward this general objective that the present invention is directed.
SUMMARY OF THE INVENTION
The present invention is a method and apparatus for terminating tachyarrhythmias such as fibrillation by the efficient delivery of electrical energy through an electrode configuration to the heart. A shock pulse output circuit in accordance with the invention includes a storage capacitor with positive and negative terminals and further includes at least three electrode lead terminals with each such electrode lead terminal switchably connected to the positive and negative capacitor terminals. Control circuitry then switches selected electrode lead terminals to either the positive or negative capacitor terminal in order to impose the capacitor voltage between electrode lead terminals and deliver a shock pulse. By serially switching selected electrode lead terminals to selected capacitor terminals, the control circuitry may thus generate a defined shock pulse waveform. For example, selected electrode lead terminals can be switched between different capacitor terminals in a manner that reverses the polarity of the voltage between the terminals to deliver a biphasic or multiphasic shock pulse. The particular electrodes used to deliver a conventional shock pulse are determined by the programming of the control circuitry, allowing for easy modification. The multi-terminal pulse output circuit also allows for more complex shock pulse waveforms to be generated by using different electrode lead terminals during the same pulse output cycle.
REFERENCES:
patent: 4998531 (1991-03-01), Bocchi et al.
patent: 5749904 (1998-05-01), Gliner et al.
patent: 5749905 (1998-05-01), Gliner et al.
patent: 5769872 (1998-06-01), Lopin et al.
patent: 5776166 (1998-07-01), Gliner et al.
patent: 5782880 (1998-07-01), Lahtinen et al.
patent: 5792189 (1998-08-01), Gray et al.
patent: 5797967 (1998-08-01), KenKnight
patent: 5797968 (1998-08-01), Lopin et al.
patent: 5800462 (1998-0
Harguth Robert S.
Larsen-Kelly Kristine M.
Ware Kurt
Cardiac Pacemakers Inc.
Hoang Johnny H.
Schwegman Lundberg Woessner & Kluth P.A.
Vo Hieu T
LandOfFree
Method and apparatus for cardiac shock therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and apparatus for cardiac shock therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and apparatus for cardiac shock therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3169329